Diagnosis and Treatment Options for Hypothyroidism Management

Gain insights into hypothyroidism diagnosis and management and enhance your understanding of thyroid health.

Abstract: What This Educational Post Covers

Welcome to this comprehensive educational resource on hypothyroidism. My name is Dr. Alex Jimenez, and throughout this post, I will take you on a carefully structured journey through one of the most prevalent yet frequently misunderstood endocrine conditions in clinical practice. Drawing on insights from leading researchers, published clinical guidelines, and my own observations documented at PushAsRx and on my professional profile, I will walk you through the full landscape of thyroid dysfunction — from its physiological foundations to its most advanced clinical management strategies.

We will begin by exploring the fundamental physiology of the hypothalamic-pituitary-thyroid (HPT) axis, then move into the classification and root causes of hypothyroidism, including Hashimoto’s thyroiditis, iodine dysregulation, medication-induced dysfunction, post-surgical and radiation-related causes, and central hypothyroidism following traumatic brain injury. We will then discuss the diagnostic process, including laboratory testing, imaging, and antibody evaluation. From there, we will examine treatment strategies in depth — covering levothyroxine (T4), liothyronine (T3), and desiccated thyroid extract (NDT) — along with the critical principles of dosing, medication administration, and the management of special populations such as older adults and patients on amiodarone.

A significant focus of this post is on an integrative care model. I will explain how chiropractic care, functional medicine, rehabilitation, and conventional medical oversight work together to address not only thyroid hormone deficiency but also its systemic consequences. I am also honored to introduce Dr. Maria Guadalupe Cardenas, MD, who has joined our team as Medical Director and Collaborative Physician at Injury Medical Clinic PA in El Paso, Texas. Her presence elevates the level of care we can offer, and together we are committed to building a truly multidisciplinary environment that places the patient at the center of every decision.

Introducing Our Multidisciplinary Team: A New Standard of Integrative Care in El Paso

One of the most meaningful developments in our practice has been the formalization of our multidisciplinary structure. I am proud to announce that Dr. Maria Guadalupe Cardenas, MD — Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933 — has joined me as Medical Director and Collaborative Physician at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas.

Dr. Cardenas brings over 40 years of distinguished experience as an internist. Her depth of knowledge in endocrinology, cardiometabolic medicine, and complex internal medicine management provides an essential foundation for the diagnostic and therapeutic work we do for patients with thyroid disease, metabolic conditions, and related disorders. Her medical authority complements my background as a Doctor of Chiropractic, an Advanced Practice Registered Nurse (Family Nurse Practitioner), and a Certified Functional Medicine Practitioner.

How Our Collaborative Model Works

This type of arrangement — an MD providing medical direction alongside a chiropractor who also holds advanced clinical credentials — is increasingly recognized as one of the most effective models in integrative and injury care settings. Here is how our team operates in practice:

• Cardenas oversees medical evaluation, diagnosis, prescription management, thyroid-specific lab and imaging interpretation, cardiovascular risk stratification, and medication reconciliation. She ensures that all interventions are medically sound, evidence-based, and safe.
• I, Dr. Jimenez, lead chiropractic care, functional medicine assessments, neuromusculoskeletal rehabilitation, nutritional strategy, and patient education. I address the biomechanical, autonomic, and lifestyle dimensions of each patient’s health picture.
• Together, we co-manage complex cases through shared care pathways, regular case reviews, and coordinated follow-up schedules. When conditions fall outside our scope, we refer you to endocrinology, neurology, or other specialists.
• Our integrated services include chiropractic adjustments, functional medicine diagnostics, personal injury rehabilitation, medical management, advanced lab interpretation, and lifestyle medicine — all under one roof.

This model exists because we believe that no single discipline holds all the answers to complex conditions like hypothyroidism. The synergy between medical oversight and integrative care produces outcomes that neither discipline could achieve alone.

Understanding Hypothyroidism: The Physiological Foundation

Before we can appreciate the nuances of diagnosis and treatment, we must understand what hypothyroidism actually is and why it affects so many body systems simultaneously.

Hypothyroidism is a clinical state characterized by the reduced production and/or action of thyroid hormone, resulting in a slowing of the body’s metabolic and thermogenic processes. At its core, thyroid hormone — particularly the active form, triiodothyronine (T3) — acts on virtually every cell in the human body. It regulates basal metabolic rate, protein synthesis, lipid metabolism, cardiovascular function, neurocognitive performance, and thermogenesis (the body’s heat production). When thyroid hormone is deficient, these processes slow down in a cascading, systemic fashion.

The Hypothalamic-Pituitary-Thyroid Axis: The Body’s Hormonal Thermostat

The regulation of thyroid hormone is governed by a tightly controlled negative feedback loop involving three levels of the endocrine hierarchy:

1. The hypothalamus releases Thyrotropin-Releasing Hormone (TRH), which travels down to the pituitary gland and signals it to act.
2. The anterior pituitary gland responds by secreting Thyroid-Stimulating Hormone (TSH), which travels through the bloodstream to the thyroid gland.
3. The thyroid gland produces thyroxine (T4) — the predominant circulating hormone — and smaller amounts of T3. T4 is largely a prohormone; it must be converted to the biologically active T3 in peripheral tissues via deiodinase enzymes.

When T3 and T4 levels are sufficient, they feed back to the hypothalamus and pituitary to suppress TRH and TSH, completing the loop. When levels fall, TRH and TSH rise in an attempt to stimulate more hormone production. This is why an elevated TSH is the hallmark laboratory finding in primary hypothyroidism — the pituitary is essentially “shouting” at a sluggish thyroid gland.

Classifying Hypothyroidism: Primary, Secondary, and Tertiary

Understanding where in this axis the dysfunction originates is critical, because it determines how we interpret labs, how we treat, and what we monitor:

• Primary Hypothyroidism: The thyroid gland itself fails to produce adequate amounts of thyroid hormone. This is the most common form, accounting for over 95% of all cases. A high TSH and low free T4 characterize it.
• Secondary (Central) Hypothyroidism: The pituitary gland fails to produce sufficient TSH, resulting in an understimulated thyroid. TSH may be low or inappropriately normal, despite low free T4. Causes include pituitary adenomas, pituitary surgery, radiation to the sellar region, or traumatic injury to the pituitary stalk.
• Tertiary Hypothyroidism: The hypothalamus fails to produce adequate TRH, disrupting the entire cascade. This is the rarest form and requires pituitary imaging and evaluation of multiple endocrine axes.

This classification matters enormously in clinical practice. In primary disease, TSH is a reliable and sensitive guide for treatment titration. In central disease, TSH cannot be trusted as a treatment target; instead, I monitor free T4 levels and the patient’s symptom resolution (Gharib et al., 2021).

The Epidemiology of Thyroid Dysfunction

Overt hypothyroidism affects an estimated 0.1% to 2% of the general population, though subclinical hypothyroidism — defined by elevated TSH with normal free T4 — is considerably more prevalent. The condition is significantly more common in women than in men, consistent with the broader pattern of autoimmune diseases disproportionately affecting females (Vanderpump, 2011). In my clinical experience, this epidemiological reality translates to a patient population that is predominantly female, often in their reproductive years or perimenopausal period, presenting with a constellation of symptoms that are frequently dismissed or misattributed to stress, aging, or depression.

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”-Video

The Root Causes of Hypothyroidism: What I Look For in Practice

In my clinical work, identifying the underlying driver of hypothyroidism is not merely academic — it directly shapes the treatment strategy. No two patients arrive at the same diagnosis by the same path.

Hashimoto’s Thyroiditis: The Most Common Cause in the United States

In the United States, the vast majority of primary hypothyroidism is caused by Hashimoto’s thyroiditis, also called chronic autoimmune lymphocytic thyroiditis. In this condition, the immune system — for reasons that involve a complex interplay of genetic susceptibility, environmental triggers, gut permeability, and hormonal factors — mistakenly identifies thyroid tissue as foreign and mounts a sustained attack against it.

The immune response produces anti-thyroid peroxidase (anti-TPO) and antithyroglobulin (anti-TgAb) antibodies. Over time, this autoimmune inflammation causes progressive destruction of thyroid follicular cells, gradually impairing the gland’s capacity to produce T4 and T3. The gland often enlarges in a goiter during the inflammatory phase, as the body attempts to compensate, before eventually becoming atrophic in late-stage disease.

From a functional medicine perspective, identifying Hashimoto’s significantly changes the treatment conversation. Rather than simply replacing the deficient hormone, we must also address the immune dysregulation at the root of the process. This involves evaluating gut integrity (since up to 70% of the immune system is housed in the gastrointestinal tract), reducing dietary triggers of inflammation, optimizing selenium and vitamin D levels, and implementing stress management strategies that modulate the hypothalamic-pituitary-adrenal axis — all of which I integrate into our clinical plans.

Iodine: Too Little and Too Much

On a global scale, iodine deficiency remains the most common cause of hypothyroidism, affecting populations in regions without widespread iodization programs (Vanderpump, 2011). Iodine is an irreplaceable structural component of both T4 (which contains four iodine atoms) and T3 (which contains three). Without adequate iodine, thyroid hormone synthesis cannot proceed.

In the United States, severe deficiency is rare due to salt iodization. Still, I always ask about iodine intake, particularly in patients following restrictive diets that eliminate iodized salt and seafood, or in those who have recently immigrated from iodine-deficient regions.

Paradoxically, excessive iodine can also suppress thyroid hormone synthesis through the Wolff-Chaikoff effect — a physiological mechanism by which a sudden large iodine load temporarily inhibits thyroid hormone production (Leung & Braverman, 2014). While healthy thyroid glands typically “escape” this inhibition within days, individuals with underlying autoimmune thyroiditis may not recover normally, leading to sustained hypothyroidism. I always screen patients for iodine-containing supplements (especially kelp and seaweed products) and ask about recent exposure to iodine-based radiocontrast agents used in imaging procedures.

Medications That Affect Thyroid Function

Several commonly used medications can impair thyroid function through distinct mechanisms:

• Lithium (used for bipolar disorder) inhibits thyroid hormone synthesis and release, and can cause both goiter and overt hypothyroidism over time.
• Amiodarone, an antiarrhythmic drug with a structure that mimics thyroid hormone and contains approximately 37% iodine by weight, can cause hypothyroidism through the Wolff-Chaikoff effect, or paradoxically can induce hyperthyroidism in iodine-deficient individuals through the Jod-Basedow phenomenon. It also potently inhibits the conversion of T4 to T3 by blocking type 1 deiodinase in peripheral tissues (Garber et al., 2012).
• Tyrosine kinase inhibitors (TKIs), used in oncology, can affect thyroid hormone metabolism and deiodination pathways.

Taking a thorough medication history is non-negotiable. I have encountered patients whose thyroid dysfunction was entirely medication-driven, and in those cases, addressing the offending agent — in collaboration with the prescribing physician — is far more appropriate than simply escalating thyroid hormone replacement.

Post-Surgical and Post-Radiation Hypothyroidism

Patients who have undergone thyroidectomy (partial or total) or radioiodine ablation for hyperthyroidism or thyroid cancer will either immediately or eventually develop hypothyroidism, as functional thyroid tissue is removed or destroyed. External beam radiation to the neck or chest — as in the treatment of lymphoma, head and neck cancers, or breast cancer — can also damage the thyroid gland over time, resulting in a gradual atrophy of functional tissue. This is a cause I must always keep in mind when reviewing a patient’s oncological history, even if the radiation was administered years or decades earlier.

Transient Hypothyroidism: Post-Illness and Post-Partum

Not all hypothyroidism is permanent. Non-thyroidal illness syndrome (NTIS), observed in critically ill patients, involves a complex pattern of altered thyroid hormone levels — typically low T3 with variable T4 and TSH — that reflects the body’s adaptive response to severe physiological stress rather than true primary thyroid failure (Fliers et al., 2015). In these situations, I avoid rushing to initiate thyroid hormone therapy. Instead, I recheck thyroid indices 4 to 6 weeks after hospital discharge to allow the HPT axis to rebalance as the acute illness resolves.

Post-partum thyroiditis follows a similar transient pattern — an initial hyperthyroid phase followed by a hypothyroid phase — in approximately 5% to 10% of women within the first year after delivery. Most of these women ultimately recover normal thyroid function, though a subset will develop permanent hypothyroidism.

Post-Concussion and Pituitary Injury: A Clinically Important but Often Missed Connection

One of the areas where my combined background in chiropractic, functional medicine, and advanced clinical practice becomes particularly valuable is in recognizing central hypothyroidism secondary to traumatic brain injury (TBI). The pituitary gland is suspended from the hypothalamus by a delicate stalk and is encased in the sella turcica — a bony cavity at the base of the skull. During acceleration-deceleration injuries such as whiplash, high-impact collisions, or repeated concussions, the pituitary stalk can be sheared, bruised, or subjected to vascular compromise through microhemorrhages and edema.

The resulting post-traumatic hypopituitarism may not manifest immediately. In my clinical observations at our injury care practice, I have seen patients who appeared neurologically intact in the acute post-injury period but developed subtle endocrine changes over the following 12 to 24 months — including low or inappropriately normal TSH with low free T4, along with fatigue, cognitive impairment, exercise intolerance, and cold sensitivity (Schneider et al., 2007).

A particularly instructive case from my practice involved a law enforcement officer who sustained a high-impact crash during a vehicle pursuit. His initial post-concussive workup was largely unremarkable on standard labs. However, over the following two years, a progressive constellation of endocrine flags emerged. Pituitary MRI and comprehensive hormonal evaluation, coordinated with Dr. Cardenas, confirmed central pituitary involvement. With a carefully titrated levothyroxine regimen guided by free T4 levels — and a phased rehabilitation program addressing vestibular function, graded exertion, and neuromuscular retraining — he returned to full professional function.

This case illustrates why I routinely screen for central endocrine dysfunction in patients presenting with significant head trauma or repetitive concussive histories. It also underscores the critical rule: in suspected central hypothyroidism, evaluate adrenal sufficiency before initiating thyroid hormone therapy, as thyroid replacement can accelerate cortisol clearance and precipitate an adrenal crisis in a patient with undiagnosed adrenal insufficiency (Garber et al., 2012).

Recognizing Hypothyroidism: Clinical Signs, Symptoms, and Physical Examination

The clinical presentation of hypothyroidism is remarkably diverse, reflecting the fact that thyroid hormone affects virtually every tissue system. The degree of symptom burden depends on the duration and severity of the deficiency, as well as individual factors including age, nutritional status, and the presence of comorbidities.

Symptoms My Patients Most Commonly Report

• Fatigue and generalized low energy, often described as “bone-deep exhaustion” that is unresponsive to sleep.
• Weight gain that feels disproportionate to dietary intake, driven by decreased basal metabolic rate
• Cold intolerance — the inability to stay warm, even in moderate temperatures — reflecting impaired thermogenesis
• Cognitive fog, poor memory, and difficulty concentrating, stemming from reduced neuronal T3 availability
• Depressed mood, which can range from mild low mood to clinically significant depression
• Dry skin, brittle nails, and hair loss (particularly diffuse thinning of scalp hair and loss of the outer third of the eyebrows)
• Constipation and slowed gastrointestinal motility.
• Menstrual irregularities and fertility challenges in women of reproductive age
• Muscle aching, stiffness, and exercise intolerance

The physiological basis for these symptoms lies in T3’s role in mitochondrial biogenesis and oxidative phosphorylation — the fundamental processes by which cells produce ATP (cellular energy). When T3 is deficient, mitochondrial efficiency drops, cells generate less energy, and nearly every physiological process slows. Two patients with identical TSH values can feel dramatically different depending on their peripheral T4-to-T3 conversion efficiency (governed by deiodinase activity), receptor sensitivity, iron and selenium status, and the degree of systemic inflammation (Bianco & da Conceição, 2018).

What I Look For on Physical Examination

My physical examination of a patient with suspected hypothyroidism includes a meticulous, head-to-toe assessment:

• Thyroid palpation: I approach the thyroid from both the back and the front, assessing the size, consistency, symmetry, and surface texture of each lobe and the isthmus. I ask the patient to swallow while I palpate, tracking gland movement and identifying any nodularity or tenderness. In Hashimoto’s, the gland often has a characteristic rubbery, heterogeneous texture and may be diffusely enlarged.
• Cervical lymph nodes: I assess anterior cervical, submental, parotid, and supraclavicular regions to evaluate for lymphadenopathy.
• Vital signs: I look for bradycardia (slowed heart rate) and diastolic hypertension, both of which reflect reduced sympathetic tone and impaired vascular compliance.
• Deep tendon reflexes: The classic finding in hypothyroidism is a delayed relaxation phase (particularly of the Achilles reflex) — a direct consequence of slowed nerve conduction velocity and impaired muscle contractility.
• Skin and hair: Dry, rough, cool, and pale skin; periorbital puffiness; myxedema — a non-pitting edema caused by the accumulation of glycosaminoglycans in interstitial tissues — in the hands, feet, and face.
• Neurological and cognitive status: I screen for cognitive slowing and mood disturbance, which can be the dominant presenting features in older patients.

Later-Stage Complications: What Happens When Hypothyroidism Goes Untreated

While my goal is always to identify and intervene before a patient reaches advanced disease, understanding the consequences of prolonged untreated hypothyroidism informs the urgency of our diagnostic and therapeutic efforts.

• Pleural effusion: Accumulation of fluid between the lungs and chest wall, detectable on chest X-ray, causing progressive dyspnea.
• Pericardial effusion: Fluid accumulation in the pericardial sac surrounding the heart, identifiable on echocardiography and associated with ECG changes.
• Myxedema coma: A rare but life-threatening emergency representing the end of untreated hypothyroidism, characterized by profound hypothermia, altered consciousness, respiratory depression, cardiovascular instability, and multi-organ failure.
• Fetal and neonatal consequences: Maternal hypothyroidism during pregnancy is associated with irreversible fetal malformations, impaired neurological development, growth retardation, and lower IQ in the offspring.
• Childhood hypothyroidism: Untreated congenital hypothyroidism can result in cretinism — severe intellectual disability, impaired psychomotor development, and stunted growth — underscoring the critical importance of newborn screening programs.

The Critical Connection Between Thyroid Function and Lipid Metabolism

One of the most clinically significant and frequently underappreciated consequences of hypothyroidism is its profound effect on lipid and cardiometabolic health. I have spent considerable time in cardiometabolic medicine, and I regularly emphasize this connection to both patients and trainees.

Thyroid hormone is a key transcriptional regulator of HMG-CoA reductase — the rate-limiting enzyme in the cholesterol biosynthesis pathway and the very target of statin medications. Thyroid hormone also upregulates hepatic LDL receptors, which are responsible for clearing LDL cholesterol from the bloodstream. When thyroid function declines, both of these mechanisms are impaired simultaneously, resulting in:

• Elevated LDL cholesterol, driven by reduced receptor-mediated clearance
• Elevated triglycerides and increased VLDL, reflecting impaired lipoprotein lipase activity
• Elevated Lipoprotein(a) [Lp(a)], an independent and particularly atherogenic cardiovascular risk factor
• Increased risk for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), as excess lipid accumulates in the liver

The clinical principle here — one emphasized by a cardiologist colleague of mine with over four decades of practice — is paramount: treat the thyroid first. When a patient presents with both hypothyroidism and dyslipidemia, initiating aggressive lipid-lowering therapy before restoring euthyroid status is frequently counterproductive. Once thyroid hormone levels are normalized, lipid panels often improve substantially on their own. Any residual dyslipidemia can then be addressed with confidence, knowing we are treating a primary lipid disorder rather than a secondary one. This is the root-cause principle in action (Biondi & Cooper, 2008).

Laboratory Evaluation: Building a Complete Diagnostic Picture

In my practice, the laboratory workup for suspected hypothyroidism extends well beyond a single TSH value. A comprehensive thyroid panel, interpreted in the context of the full clinical picture, is essential for accurate diagnosis and individualized treatment.

Core Thyroid Testing

• TSH (Thyrotropin): The most sensitive screening test for primary hypothyroidism. An elevated TSH indicates that the pituitary is working harder to compensate for insufficient thyroid hormone production. In central hypothyroidism, TSH may be low, normal, or mildly elevated despite low free T4 — making it an unreliable standalone marker in that context.
• Free T4: Reflects the amount of unbound, bioavailable thyroxine circulating in the bloodstream. A low free T4 in the presence of elevated TSH confirms overt primary hypothyroidism; a low free T4 with low or normal TSH points toward central hypothyroidism.
• Free T3: While not universally required, free T3 is valuable in patients who remain symptomatic despite normalized TSH and free T4, as it may reveal impaired peripheral conversion of T4 to the active form, T3.
• Anti-TPO and antithyroglobulin antibodies: Essential for identifying autoimmune thyroiditis (Hashimoto’s). Anti-TPO positivity carries independent prognostic significance, substantially increasing the risk of progression from subclinical to overt hypothyroidism.
• TSI (Thyroid-Stimulating Immunoglobulin): Useful when Graves’ disease or Hashitoxicosis (the hyperthyroid phase sometimes seen in Hashimoto’s) is in the differential diagnosis.

Systemic Laboratory Assessment

Because hypothyroidism affects multiple organ systems, I routinely evaluate:

• Lipid panel (LDL, HDL, triglycerides, non-HDL, Lp(a)): To assess cardiometabolic risk and establish a pre-treatment baseline.
• Complete blood count (CBC): Hypothyroidism can cause normocytic or macrocytic anemia through impaired erythropoiesis and reduced erythropoietin response.
• Comprehensive metabolic panel: Monitoring for hyponatremia (caused by impaired free water excretion and reduced cardiac output) and hepatic function.
• Creatine kinase (CK): Elevated in hypothyroid myopathy, a common but underrecognized cause of muscle pain and weakness in hypothyroid patients.
• Prolactin: TRH cross-stimulates prolactin secretion; elevated prolactin can be a secondary marker of hypothyroidism and of pituitary pathology.
• Ferritin and iron studies: Iron deficiency impairs thyroid peroxidase (TPO) activity — the enzyme responsible for thyroid hormone synthesis — meaning that iron-deficient patients may not respond optimally to levothyroxine therapy. I target a ferritin level of 50- 70 ng/mL in thyroid patients.
• In suspected central hypothyroidism: Morning cortisol, ACTH stimulation testing, LH/FSH, IGF-1, growth hormone, and pituitary MRI to comprehensively evaluate all axes of pituitary function.

Timing of Retesting in Post-Illness Scenarios

When evaluating thyroid function in patients recently discharged from an intensive care setting or recovering from severe systemic illness, I delay retesting for 4 to 6 weeks after hospital discharge. This allows the HPT axis to normalize as the acute inflammatory and catabolic state resolves. Premature testing in the context of non-thyroidal illness syndrome frequently yields misleading results and can lead to inappropriate initiation of thyroid hormone therapy (Fliers et al., 2015).

Thyroid Imaging: When and Why Ultrasound Matters

Thyroid ultrasound is the imaging modality of choice when structural questions arise. It is safe, non-ionizing, widely available, and highly sensitive to changes in gland architecture. I order ultrasound in the following circumstances:

• Suspected or confirmed Hashimoto’s: A diffusely enlarged, heterogeneous gland with a coarsened echotexture and hypoechoic parenchyma on ultrasound is the classic finding in chronic autoimmune thyroiditis. Fibrotic echogenic bands may also be visible in longer-standing disease.
• Palpable nodule or incidentally discovered nodule: Focal thyroid nodules require characterization using the ACR TI-RADS (Thyroid Imaging Reporting and Data System) criteria to guide risk stratification and determine whether fine-needle aspiration (FNA) biopsy is warranted (Tessler et al., 2017).
• Goiter: To assess gland volume, texture, and the presence of nodular changes.

In central hypothyroidism, the thyroid gland itself may appear structurally normal on ultrasound, since the failure lies upstream in the pituitary or hypothalamus. In these cases, pituitary MRI is far more informative.

Subclinical Hypothyroidism: Navigating the Gray Zone

Subclinical hypothyroidism — defined as a TSH between approximately 5 and 10 mIU/L with a normal free T4 — is one of the most nuanced and clinically challenging areas of thyroid medicine. Many patients in this range feel entirely well, while others present with a full constellation of hypothyroid symptoms. The laboratory definition doesn’t capture this heterogeneity, which is why I prefer to treat the patient rather than the number.

When I Consider Treatment for Subclinical Hypothyroidism

My decision-making framework incorporates the following considerations:

• Symptom burden: Does the patient have clinically meaningful fatigue, cognitive impairment, or mood disturbance attributable to thyroid dysfunction?
• Anti-TPO antibody status: Positive antibodies indicate an autoimmune process with a substantially higher likelihood of progression to overt hypothyroidism.
• TSH trajectory: A TSH that is trending upward over sequential measurements carries more clinical weight than a stable mildly elevated value.
• Cardiometabolic risk: Elevated LDL and triglyceride levels, along with endothelial dysfunction associated with subclinical disease, may favor treatment, particularly in patients with existing cardiovascular risk factors (Biondi & Cooper, 2008).
• Age: In older adults (typically over 65), mild TSH elevations may actually represent a physiological adaptation and may not require treatment. However, in younger patients and in women of reproductive age or planning pregnancy, more proactive treatment is often appropriate.
• TSH above 10 mIU/L: At this threshold, I generally recommend treatment regardless of symptoms, given the elevated risk of cardiovascular complications and disease progression (Gharib et al., 2021).

A Clarification on Wilson’s Temperature Syndrome

Patients occasionally present having researched “Wilson’s temperature syndrome” — a proposed but unvalidated clinical entity characterized by low body temperature and hypothyroid-like symptoms, purportedly treated with high-dose T3. I address this topic with transparency and scientific integrity. Current evidence does not support this as a legitimate diagnosis, and major endocrine societies, including the American Thyroid Association, advise against this label (American Thyroid Association, 2005). It is important to distinguish this from Wilson’s disease — a well-characterized genetic disorder of copper metabolism with hepatic and neurological manifestations — which is an entirely unrelated condition. When patients present with nonspecific symptoms, I rely on validated laboratory testing, a systematic differential diagnosis, and shared clinical decision-making to arrive at an accurate diagnosis.

Treatment Goals: Restoring Function, Not Just Normalizing Numbers

Before discussing specific treatments, it is essential to articulate what we are actually trying to achieve. Our treatment goals in hypothyroidism are:

1. Resolution of symptoms: Alleviating the patient’s fatigue, cognitive fog, weight gain, cold intolerance, and other manifestations that impair quality of life.
2. Normalization of biochemical markers: Achieving a serum TSH within the age-appropriate reference range, alongside healthy free T4 and free T3 levels.
3. Prevention of long-term complications: Reducing cardiometabolic risk, preventing myxedema, and — in women of reproductive age — protecting fetal neurodevelopment during pregnancy.
4. Avoiding iatrogenic thyrotoxicosis: Over-replacement is not benign. Excess thyroid hormone can cause atrial fibrillation, accelerated bone loss, anxiety, and cardiovascular strain. This risk is particularly elevated in older adults and those with underlying cardiac disease.

The mantra I return to consistently is: we treat people, not paper. If a patient’s TSH is perfectly normal but they tell me they still feel miserable, my clinical obligation is not satisfied. Conversely, if a patient’s TSH is mildly low but they feel well and have no symptoms of thyrotoxicosis, an immediate dose reduction may not serve their best interests. Clinical judgment, patient experience, and laboratory data must all be integrated.

Treatment Options for Hypothyroidism: Understanding the Evidence

Levothyroxine (T4): The Evidence-Based First-Line Standard

Levothyroxine — a synthetic form of thyroxine (T4) — is the standard first-line treatment for all forms of hypothyroidism, as recommended by the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) (Garber et al., 2012). Several important pharmacological properties justify its clinical dominance:

• Long half-life (~5 to 7 days): T4’s extended half-life provides remarkably stable circulating hormone levels with once-daily dosing, minimizing peaks and troughs that can destabilize patients.
• Natural conversion to T3: Administered T4 is converted to the active T3 by peripheral deiodinase enzymes, allowing the body’s own regulatory mechanisms to govern T3 availability at the tissue level.
• Well-established safety profile: Decades of clinical use and robust post-marketing data support its safety when dosed appropriately.

One practical issue I emphasize to patients is the brand-versus-generic debate. The FDA permits generic medications to have a bioequivalence range of 80% to 125% of the stated dose. For most drugs, this range is clinically inconsequential. For levothyroxine — a hormone with a narrow therapeutic window — switching between different generic formulations or between brand and generic can introduce meaningful variability in TSH levels. Whenever feasible, I recommend patients stay on the same formulation consistently, whether brand-name or a single consistent generic.

Liothyronine (T3): A Targeted Tool for Select Patients

Liothyronine (synthetic T3, brand names Cytomel and Triostat) is not a standard first-line therapy. Still, it is an invaluable adjunct for patients who continue to experience symptoms despite optimal levothyroxine therapy and normalized TSH. This persistent symptom burden in a subset of patients is thought to reflect impaired peripheral T4-to-T3 conversion due to polymorphisms in deiodinase genes, nutritional deficiencies, or chronic inflammation.

The pharmacological challenge with T3 is its short half-life of approximately 24 hours, which leads to more pronounced peaks and troughs in hormone levels than with T4. This often necessitates twice-daily dosing and requires careful monitoring. However, for the right patient — one whose tissue T3 levels remain suboptimal despite adequate T4 replacement — liothyronine can be genuinely life-changing (Jonklaas et al., 2014).

Desiccated Thyroid Extract (NDT): A Historical and Contemporary Option

Desiccated thyroid extract (NDT) — derived from the dried and powdered thyroid glands of pigs (e.g., Armor Thyroid, NP Thyroid) — is the oldest form of thyroid hormone replacement, predating synthetic alternatives by many decades. It contains both T4 and T3 in a fixed ratio: one grain (approximately 65 mg) of Armor Thyroid provides roughly 38 mcg of T4 and 9 mcg of T3.

NDT is not a first-line recommendation from major endocrine societies, largely due to its fixed T4:T3 ratio and relatively high T3 content compared with human thyroid physiology. However, many patients who have not achieved satisfactory symptom resolution on levothyroxine alone report significant clinical improvement on NDT. Dosing requires patience and careful monitoring, particularly given the variable half-life resulting from the combined T4 and T3 content (Patil & Rehman, 2023). In my practice, I consider NDT on a case-by-case basis, in collaboration with Dr. Cardenas, when standard monotherapy has been optimized. Still, the patient’s quality of life remains significantly impaired.

The Art of Dosing: Going Low and Slow

The foundational principle of initiating thyroid hormone therapy is “go low and slow.” This is not merely a catchphrase — it reflects the physiological reality that thyroid hormone acts on every cell in the body, and that suddenly flooding tissues with supraphysiological amounts of T4 can provoke significant adverse effects, particularly in the cardiovascular and skeletal systems.

Practical Dosing Framework

• Starting dose: I typically initiate levothyroxine at 25-50 micrograms per day in most adults. In older adults, particularly those with coronary artery disease, I may begin as low as 5 to 25 mcg/day.
• Weight-based estimation: A commonly used guideline is a full replacement dose of 1.6-1.8 mcg/kg body weight per day. For a 70 kg adult, this would suggest a target dose of approximately 112-126 mcg/day. However, I use this calculation only as a rough guide for eventual target dosing — I never start at the full calculated dose.
• Titration intervals: TSH is rechecked 6 to 8 weeks after any dose initiation or adjustment to allow sufficient time for the HPT axis to reach a new equilibrium.
• Dose increments: Adjustments are made in 5-25 mcg increments, increasing gradually until the patient’s TSH falls within the target range and symptoms resolve.
• Typical maintenance range: The majority of patients (approximately 80% to 90%) will achieve clinical and biochemical euthyroidism on a dose between 100 and 200 mcg/day.
• TSH targets by age: In younger adults, a TSH of 1.0-2.5 mIU/L is a reasonable target. In older adults (over 65), a slightly higher target of 2.0 to 4.0 mIU/L may be appropriate to avoid over-suppression.

How to Take Levothyroxine Correctly

Improper medication administration is one of the most common — and most easily correctable — causes of treatment failure. I review these instructions at virtually every patient visit:

• Take it on an empty stomach, first thing in the morning, before eating or drinking anything other than plain water.
• Use a full glass of water to ensure complete swallowing and initiate dissolution.
• Wait 45 to 60 minutes before eating, drinking coffee, or taking any other medications, vitamins, or supplements.
• Avoid calcium and iron within 4 hours of taking levothyroxine, as both bind to the medication in the gastrointestinal tract and significantly reduce absorption. Proton pump inhibitors (PPIs) and bile acid sequestrants also impair absorption.
• A practical tip I share with patients: keep the pill bottle and a glass of water on the bedside table. Take the medication immediately upon waking — before showering, exercising, or preparing breakfast. By the time the morning routine is complete, the 60-minute waiting window will have passed naturally.

Special Clinical Scenarios: Amiodarone, Adrenal Insufficiency, and Older Adults

Amiodarone-Induced Thyroid Dysfunction

Amiodarone is a particularly complex medication in the context of thyroid management. As noted earlier, its high iodine content and structural similarity to T4 allow it to interfere with thyroid function through multiple simultaneous mechanisms: it inhibits peripheral T4-to-T3 conversion, can trigger the Wolff-Chaikoff effect, can induce destructive thyroiditis, and may also paradoxically cause hyperthyroidism (the Jod-Basedow effect). Managing thyroid function in a patient on amiodarone requires close collaboration between the internist or cardiologist managing the arrhythmia and the practitioner overseeing thyroid care (Garber et al., 2012). Thyroid function should be monitored at least every 6 to 12 months in these patients, and any decision to modify thyroid therapy must take into account the underlying cardiac condition.

Adrenal Insufficiency and Schmidt’s Syndrome

Before initiating thyroid hormone therapy — particularly in patients with suspected central hypothyroidism or those with autoimmune thyroid disease — I always consider the possibility of concurrent adrenal insufficiency. Thyroid hormone replacement increases the metabolic clearance rate of cortisol; in a patient with undiagnosed Addison’s disease or adrenal insufficiency, this can precipitate a life-threatening adrenal crisis.

Schmidt’s syndrome (also known as Autoimmune Polyendocrine Syndrome Type 2, APS-2) is the co-occurrence of autoimmune thyroid disease, autoimmune adrenal insufficiency (Addison’s disease), and often Type 1 diabetes mellitus. When I encounter a patient with Hashimoto’s thyroiditis, I maintain a low threshold for screening cortisol and ACTH levels, particularly if the patient reports unexplained fatigue, hypotension, hyperpigmentation, or sodium imbalance. Treating the thyroid without first ensuring adrenal adequacy can be clinically catastrophic (Garber et al., 2012).

Treating Older Adults: Extra Caution Is Non-Negotiable

In patients over 65 — and especially those with underlying coronary artery disease, heart failure, atrial fibrillation, or other cardiopulmonary conditions — the “go low and slow” principle is not just a preference; it is a clinical imperative. The aging cardiovascular system is significantly more sensitive to the chronotropic and inotropic effects of excess thyroid hormone. Starting at too high a dose or escalating too quickly can precipitate tachycardia, angina, arrhythmias, or acute cardiac decompensation (Hennessey & Espaillat, 2015).

In this population, I often target a slightly higher TSH range (2.0 to 4.0 mIU/L) to provide an adequate safety margin. Close symptom monitoring and regular cardiac assessment are integrated into the follow-up plan.

Clinical Case Studies: Applying Principles to Real Patients

Case Study 1: Sally, a 24-Year-Old Graduate Student with Hashimoto’s Thyroiditis

Presenting complaints: Fatigue, a 4-pound weight gain, and a history of depression. Family history significant for Hashimoto’s disease.

Physical examination: Slightly enlarged thyroid gland (estimated 35 grams), dry skin.

Laboratory results:

• TSH: 6.0 mIU/L (mildly elevated)
• Anti-TPO antibodies: 1,100 IU/mL (significantly elevated; normal <35)
• Free T3 and free T4: Normal

Ultrasound: Diffusely enlarged thyroid with heterogeneous echotexture — classic for chronic autoimmune thyroiditis.

Diagnosis: Subclinical hypothyroidism secondary to Hashimoto’s thyroiditis.

Treatment decision: A full weight-based calculation suggested a target dose range of 115-129 mcg/day. This figure would have been far too aggressive for a young woman with subclinical disease and normal free hormone levels. Instead, I initiated therapy at 25 mcg of levothyroxine daily, the lowest available therapeutic dose. The rationale was to provide a gentle physiological nudge without overwhelming her system.

Six-week follow-up:

• TSH normalized to 5 mIU/L
• Free T3 and T4 remained stable and healthy
• Patient reported marked improvement in energy levels and a noticeable improvement in mood and cognitive clarity.

TPO antibodies, while still elevated, were not treated as a direct therapeutic target — antibody titers fluctuate and do not reliably track disease activity. The ongoing monitoring plan includes annual laboratory testing, periodic thyroid ultrasound, and earlier evaluation if symptoms recur. Sally’s case is a compelling demonstration that a small, thoughtfully chosen dose can produce a transformative clinical response.

Case Study 2: Jane, a 52-Year-Old Postmenopausal Woman with Radiation-Related Hypothyroidism

Relevant history: Ductal carcinoma in situ (DCIS) of the breast at age 42, treated with lumpectomy and chest wall radiation (no chemotherapy). Current comorbidities: hypertension, obesity, prediabetes, total hysterectomy at age 40. Current medications: levothyroxine, telmisartan, metformin.

Laboratory and imaging findings:

• TSH: 0 mIU/L (overt hypothyroidism)
• Free T4 and free T3: Low normal
• Thyroid ultrasound: Atrophic thyroid gland — consistent with long-term radiation-induced damage to the gland from her breast cancer treatment a decade earlier

Clinical approach: Jane was already on levothyroxine, so the elevated TSH signaled that her current dose of 112 mcg was no longer sufficient. Before simply raising the dose, I systematically explored the most common reasons for treatment failure:

1. Was she taking her medication every single day?
2. Was she taking it correctly — on an empty stomach, with water, before other medications?
3. Had her pharmacy switched her from brand-name to generic, or between different generics?
4. Were there any financial, logistical, or social barriers to consistent access to prescriptions?

With these factors assessed and her current dose confirmed as genuinely inadequate, I calculated her weight-based target. At 84 kg, her estimated full replacement dose was 134 to 151 mcg/day. Consistent with the “go low and slow” principle, I increased her dose from 112 mcg to the next available strength: 125 mcg daily.

Outcome: At six-week follow-up, her TSH had returned to the normal range, and she reported a meaningful improvement in energy and overall well-being. Jane’s case highlights the importance of always searching for root causes before escalating therapy, and the lasting consequences of cancer treatment on endocrine function.

Case Study 3: John, a 74-Year-Old Man on Amiodarone with Cardiovascular Disease

Relevant history: Long-standing hypothyroidism, hypertension, cardiac arrhythmia managed with amiodarone. Currently stable on levothyroxine 125 mcg daily.

Clinical picture: John’s lab work appeared well-controlled, and his thyroid ultrasound showed no structural abnormalities. His case exemplifies the principle that stability in a complex patient requires vigilance, not complacency. Given amiodarone’s capacity to alter thyroid function through multiple mechanisms — including inhibition of T4-to-T3 conversion and iodine-mediated effects — I schedule his thyroid function testing every 6 to 12 months and conduct medication administration counseling at every visit.

The critical take-home lesson from John’s case: in patients with cardiovascular comorbidities and confounding medications, meticulous monitoring is as therapeutically important as the prescription itself.

The Integrative Chiropractic and Functional Medicine Dimension

Perhaps the most distinctive aspect of our approach at Injury Medical Clinic PA is the integration of chiropractic care, functional medicine, and rehabilitative services into the management of hypothyroidism. This is not a superficial pairing — it reflects a genuinely physiological rationale for why these disciplines contribute meaningfully to thyroid-related health outcomes.

Chiropractic Care and Neurological Regulation

The spine and central nervous system form the master regulatory network of the human body. The hypothalamic-pituitary-thyroid axis is ultimately a neurohormonal system — dependent on intact signaling from the central nervous system. Mechanical dysfunction in the cervical spine, including segmental restrictions, altered joint kinematics, and nociceptive drive from injured or dysfunctional cervical structures, can influence autonomic nervous system tone and thereby affect hypothalamic-pituitary signaling.

Through precise chiropractic adjustments — particularly in the upper cervical spine — I work to restore optimal joint mobility, reduce nociceptive input, and support the neurological environment in which endocrine regulation occurs. While chiropractic care does not replace thyroid hormone when true deficiency exists, it contributes to the broader physiological milieu that supports endocrine function, reduces systemic stress responses, and improves the patient’s capacity to engage in lifestyle changes that potentiate the effects of medical treatment.

Rehabilitation: Restoring Metabolic Capacity

Hypothyroidism impairs mitochondrial efficiency, reduces cardiovascular conditioning, and decreases muscle mass — all of which worsen fatigue, metabolic rate, and insulin sensitivity. A structured progressive rehabilitation program directly counteracts these effects.

In my rehabilitation protocols, I employ:

• Low-to-moderate intensity progressive resistance training, scaled to the patient’s current fitness and symptom burden, targeting an RPE (Rate of Perceived Exertion) of 3 to 5 on a 10-point scale
• Interval walking to improve cardiorespiratory fitness without overwhelming the patient
• Breathing retraining and vagal toning exercises to reduce sympathetic overdrive, which is chronically elevated in patients with fatigue and sleep disruption
• Postural correction to address the forward head posture and thoracic kyphosis that commonly develop in hypothyroid patients due to reduced energy for postural maintenance

Resistance training, in particular, is known to upregulate mitochondrial biogenesis via PGC-1α pathways and improve insulin receptor sensitivity — both of which are directly relevant to the metabolic dysfunction that accompanies hypothyroidism. By improving the body’s cellular energy efficiency, we help patients feel better even before thyroid hormone levels have fully normalized, and we dramatically amplify the benefits of medical therapy once it is instituted.

Functional Medicine: Addressing the Root Causes of Thyroid Dysfunction

As a Certified Functional Medicine Practitioner, I approach hypothyroidism through a systems-based lens that looks for the underlying biological imbalances driving dysfunction:

• Selenium optimization: Selenium is a critical cofactor for both type 1 deiodinase (responsible for peripheral T4-to-T3 conversion) and glutathione peroxidase (a key antioxidant enzyme that protects thyroid tissue from oxidative damage). Evidence supports 50- 200 mcg/day of selenomethionine to modulate thyroid autoimmunity, particularly in patients with Hashimoto’s (Ventura et al., 2017). I personalize dosing based on dietary intake assessment and laboratory selenium levels.
• Iron and ferritin optimization: As previously noted, iron deficiency impairs TPO activity and blunts the response to levothyroxine. I target a ferritin of 50 to 70 ng/mL, coordinating iron repletion with Dr. Cardenas as needed.
• Iodine stewardship: I screen for excess iodine sources before considering any supplementation. In patients with confirmed iodine deficiency, I address it cautiously, as aggressive iodine supplementation in Hashimoto’s patients can paradoxically worsen autoimmune activity.
• Anti-inflammatory dietary strategy: An emphasis on omega-3 fatty acids, phytonutrient-dense vegetables, adequate high-quality protein, and dietary fiber supports lipid management, gut integrity, and immune modulation — all of which are relevant to the autoimmune and cardiometabolic dimensions of hypothyroidism.
• Sleep and circadian rhythm optimization: Sleep disruption dysregulates the HPT axis and impairs immune function. Evidence-based sleep hygiene interventions, including circadian alignment strategies, form an essential component of our functional medicine protocol.
• Gut health evaluation: Given the established role of intestinal permeability (“leaky gut”) in the pathogenesis of autoimmune diseases, I assess gut function in all patients with Hashimoto’s and address dysbiosis, permeability, and food sensitivities as part of the integrative plan.

When to Refer to Endocrinology

While the majority of hypothyroid patients can be effectively managed in an integrative primary care setting like ours, certain clinical scenarios warrant referral to an endocrinologist:

• Dose escalation beyond 2.0 mcg/kg/day without achieving stable euthyroidism — suggesting malabsorption, non-adherence, or an unusual underlying condition
• Persistent symptoms despite biochemically normalized TSH and free T4, particularly if combination T4/T3 therapy or NDT is being considered
• Suspected secondary or tertiary hypothyroidism requiring comprehensive pituitary evaluation
• Unusual or discordant lab patterns that do not conform to expected primary thyroid disease
• Pregnancy in patients with known thyroid disease, due to the complexity of thyroid management during gestation and the critical importance of fetal neurodevelopment

Before making a referral, I always revisit the fundamentals: confirm medication adherence, review administration technique, check for drug interactions, and evaluate whether a formulary or pharmacy change may have altered bioavailability.

Step-by-Step Diagnostic Pathway We Use at Injury Medical Clinic PA

History

• Recent radiation or surgery to the neck or chest
• Medications: lithium, amiodarone, TKIs; iodine-containing supplements or kelp products
• Severe recent illness or ICU admission
• Pregnancy or post-partum within the past 12 months
• Head trauma, whiplash, or multiple concussive injuries
• Family history of autoimmune thyroid or adrenal disease

Physical Examination

• Thyroid palpation (size, consistency, nodularity, tenderness)
• Cervical lymph node assessment
• Vital signs (bradycardia, diastolic hypertension)
• Deep tendon reflexes (delayed relaxation phase)
• Skin, hair, and nail examination
• Periorbital and peripheral edema assessment
• Cognitive and mood screening

Laboratory Testing

• TSH, free T4 ± free T3
• Anti-TPO and antithyroglobulin antibodies
• Lipid panel, CBC, comprehensive metabolic panel
• CK, prolactin, ferritin/iron studies
• In central disease: morning cortisol, ACTH, LH/FSH, IGF-1, and pituitary MRI

Imaging

• Thyroid ultrasound for parenchymal texture, goiter, and nodule characterization (ACR TI-RADS)
• Pituitary MRI in suspected central hypothyroidism

Monitoring Schedule

• Recheck TSH and free T4 every 6 to 8 weeks after any dose change
• Recheck every 4 to 6 weeks post-hospitalization or post-illness before initiating therapy
• Stable patients: annual thyroid function testing; ultrasound every 1 to 2 years in Hashimoto’s
• Amiodarone patients: thyroid function every 6 to 12 months

Key Clinical Takeaways for Understanding and Managing Hypothyroidism

• Think broadly about causes: Iodine dysregulation, medications, surgery, radiation, severe illness, and head trauma can all disrupt the HPT axis through distinct mechanisms.
• Localize the dysfunction: The distinction between primary and central hypothyroidism fundamentally changes lab interpretation, treatment targets, and monitoring strategy.
• Use antibodies wisely: Anti-TPO positivity is a meaningful prognostic marker, but antibody titers are not direct treatment targets and fluctuate independently of clinical status.
• Prioritize the thyroid in dyslipidemia: Treat hypothyroidism first, then reassess lipid status after euthyroidism is restored before escalating lipid-lowering therapy.
• Integrate cardiometabolic care: Subclinical disease can affect lipids, endothelial function, and cardiac risk; integrating lifestyle and rehabilitative strategies alongside medical management produces superior outcomes.
• Monitor with clinical intent: Reassess every 4 to 8 weeks when the clinical context changes; avoid premature intervention for transient post-illness thyroid changes.
• Address the whole patient: Chiropractic care, sleep optimization, nutritional strategy, selenium and iron adequacy, and progressive rehabilitation potentiate the benefits of thyroid hormone therapy and improve quality of life in ways that medication alone cannot.

References

• American Thyroid Association. (2005). ATA statement on “Wilson’s syndrome.” Thyroid, 15(5), 537–538.
• Bianco, A. C., & da Conceição, R. R. (2018). Thyroid hormone signaling in health and disease. Endocrine Reviews, 39(3), 217–242.
• Biondi, B., & Cooper, D. S. (2008). The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29(1), 76–131.
• Brown, R. S., Bellisario, R. L., Botero, D., Fournier, L., Abrams, C. A., Cowger, M. L., David, R., Fort, P., & Richman, R. A. (2018). Genetic causes of congenital hypothyroidism. Pediatric Research, 83(1–2), 168–176.
• Fliers, E., Bianco, A. C., Langouche, L., & Boelen, A. (2015). Critical illness and thyroid hormone metabolism. Thyroid, 25(7), 767–779.
• Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012). Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22(12), 1200–1235.
• Gharib, H., Papini, E., Garber, J. R., Duick, D. S., Harrell, R. M., Hegedus, L., Paschke, R., Valcavi, R., & Vitti, P. (2021). Subclinical thyroid dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Journal of Clinical Endocrinology and Metabolism, 106(6), e2493–e2526.
• Hennessey, J. V., & Espaillat, R. (2015). Diagnosis and management of subclinical hypothyroidism in elderly adults: A review of the literature. Journal of the American Geriatrics Society, 63(8), 1663–1673.
• Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid, 24(12), 1670–1751.
• Leung, A. M., & Braverman, L. E. (2014). Consequences of excess iodine. Nature Reviews Endocrinology, 10(3), 136–142.
• Leung, A. M., Lamar, A., He, X., Braverman, L. E., & Pearce, E. N. (2012). Iodine status and thyroid function of Boston-area vegetarians and vegans. Endocrine Practice, 18(4), 562–567.
• Patil, N., & Rehman, A. (2023). Desiccated thyroid extract. In StatPearls [Internet]. StatPearls Publishing.
• Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., & Walter, M. A. (2016). 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 26(10), 1343–1421.
• Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G. K., & Ghigo, E. (2007). Hypopituitarism. Lancet, 369(9571), 1461–1470.
• Tessler, F. N., Middleton, W. D., Grant, E. G., Hoang, J. K., Berland, L. L., Teefey, S. A., Cronan, J. J., Beland, M. D., Desser, T. S., Frates, M. C., Hammers, L. W., Hamper, U. M., Langer, J. E., Reading, C. C., Scoutt, L. M., & Stavros, A. T. (2017). ACR thyroid imaging, reporting and data system (TI-RADS): White paper of the ACR TI-RADS committee. Journal of the American College of Radiology, 14(5), 587–595.
• Vanderpump, M. P. J. (2011). The epidemiology of thyroid disease. British Medical Bulletin, 99(1), 39–51.
• Ventura, M., Melo, M., & Carrilho, F. (2017). Selenium and thyroid disease: From pathophysiology to treatment. International Journal of Endocrinology, 2017, 1297658.
• PushAsRx Performance. (n.d.). Clinical observations and rehabilitation insights.
• Jimenez, A. (n.d.). Professional profile and clinical updates. LinkedIn.

SEO Tags: hypothyroidism, Hashimoto’s thyroiditis, subclinical hypothyroidism, overt hypothyroidism, central hypothyroidism, pituitary injury, post-concussion hypothyroidism, integrative chiropractic care, functional medicine, thyroid hormone replacement, levothyroxine dosing, liothyronine T3 therapy, desiccated thyroid extract, TSH, free T4, free T3, thyroid antibodies, anti-TPO, thyroid ultrasound, TI-RADS, selenium thyroid, iodine excess, Wolff-Chaikoff effect, dyslipidemia hypothyroidism, cholesterol thyroid, cardiometabolic health, HMG-CoA reductase, amiodarone thyroid dysfunction, adrenal insufficiency, Schmidt’s syndrome, APS-2, myxedema coma, go low and slow thyroid, rehabilitation hypothyroidism, personal injury clinic El Paso, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso Texas, multidisciplinary healthcare, evidence-based endocrinology, HPT axis, hypothalamic pituitary thyroid axis, patient-centered thyroid care